These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 28475150)

  • 21. Pu-erh tea extract ameliorates high-fat diet-induced nonalcoholic steatohepatitis and insulin resistance by modulating hepatic IL-6/STAT3 signaling in mice.
    Cai X; Fang C; Hayashi S; Hao S; Zhao M; Tsutsui H; Nishiguchi S; Sheng J
    J Gastroenterol; 2016 Aug; 51(8):819-29. PubMed ID: 26794005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of citrate cotransporter Slc13a5/mINDY by RNAi improves hepatic insulin sensitivity and prevents diet-induced non-alcoholic fatty liver disease in mice.
    Brachs S; Winkel AF; Tang H; Birkenfeld AL; Brunner B; Jahn-Hofmann K; Margerie D; Ruetten H; Schmoll D; Spranger J
    Mol Metab; 2016 Nov; 5(11):1072-1082. PubMed ID: 27818933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concurrent exercise improves insulin resistance and nonalcoholic fatty liver disease by upregulating PPAR-γ and genes involved in the beta-oxidation of fatty acids in ApoE-KO mice fed a high-fat diet.
    Zheng F; Cai Y
    Lipids Health Dis; 2019 Jan; 18(1):6. PubMed ID: 30611282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacotherapy of nonalcoholic steatohepatitis: Reflections on the existing evidence.
    Tang JT; Mao YM
    J Dig Dis; 2017 Nov; 18(11):607-617. PubMed ID: 29106066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Intestinal Microbiome in Nonalcoholic Fatty Liver Disease.
    Puri P; Sanyal AJ
    Clin Liver Dis; 2018 Feb; 22(1):121-132. PubMed ID: 29128052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunomodulatory liposomes targeting liver macrophages arrest progression of nonalcoholic steatohepatitis.
    Maradana MR; Yekollu SK; Zeng B; Ellis J; Clouston A; Miller G; Talekar M; Bhuyan ZA; Mahadevaiah S; Powell EE; Irvine KM; Thomas R; O'Sullivan BJ
    Metabolism; 2018 Jan; 78():80-94. PubMed ID: 28941597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Altered distribution of regulatory lymphocytes by oral administration of soy-extracts exerts a hepatoprotective effect alleviating immune mediated liver injury, non-alcoholic steatohepatitis and insulin resistance.
    Khoury T; Ben Ya'acov A; Shabat Y; Zolotarovya L; Snir R; Ilan Y
    World J Gastroenterol; 2015 Jun; 21(24):7443-56. PubMed ID: 26139990
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic phenotype and adipose and liver features in a high-fat Western diet-induced mouse model of obesity-linked NAFLD.
    Luo Y; Burrington CM; Graff EC; Zhang J; Judd RL; Suksaranjit P; Kaewpoowat Q; Davenport SK; O'Neill AM; Greene MW
    Am J Physiol Endocrinol Metab; 2016 Mar; 310(6):E418-39. PubMed ID: 26670487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Haptoglobin Genotype and Vitamin E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design.
    Zang S; Chen J; Song Y; Bai L; Chen J; Chi X; He F; Sheng H; Wang J; Xie S; Xie W; Yang Y; Zhang J; Zheng M; Zou Z; Wang B; Shi J;
    Adv Ther; 2018 Feb; 35(2):218-231. PubMed ID: 29411270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endogenous IL-33 has no effect on the progression of fibrosis during experimental steatohepatitis.
    Vasseur P; Dion S; Filliol A; Genet V; Lucas-Clerc C; Jean-Philippe G; Silvain C; Lecron JC; Piquet-Pellorce C; Samson M
    Oncotarget; 2017 Jul; 8(30):48563-48574. PubMed ID: 28611297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Letter to the Editor: Patient-Reported Outcomes for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis: Rationale for Expanded Use.
    Carrieri P; Duracinsky M; Marcellin F; Lazarus JV
    Hepatology; 2019 Jul; 70(1):443-444. PubMed ID: 30472796
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome: A propensity score-matched cohort study.
    Kim GH; Chung JW; Lee JH; Ok KS; Jang ES; Kim J; Shin CM; Park YS; Hwang JH; Jeong SH; Kim N; Lee DH; Kim JW
    Clin Mol Hepatol; 2015 Dec; 21(4):379-86. PubMed ID: 26770927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Letter to the editor about "the effect of a fruit-rich diet on liver biomarkers, insulin resistance, and lipid profile in patients with non-alcoholic fatty liver disease: a randomized clinical trial".
    Soto-Mota A; Perichart-Perera O
    Scand J Gastroenterol; 2023 Feb; 58(2):222. PubMed ID: 36039493
    [No Abstract]   [Full Text] [Related]  

  • 35. Cangju Qinggan Jiangzhi Decoction Reduces the Development of NonAlcoholic Steatohepatitis and Activation of Kupffer Cells.
    Cheng Y; Chen T; Ping J; Chen J
    Cell Physiol Biochem; 2018; 48(3):971-982. PubMed ID: 30036865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preventive effects of citrulline on Western diet-induced non-alcoholic fatty liver disease in rats.
    Jegatheesan P; Beutheu S; Freese K; Waligora-Dupriet AJ; Nubret E; Butel MJ; Bergheim I; De Bandt JP
    Br J Nutr; 2016 Jul; 116(2):191-203. PubMed ID: 27197843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial.
    Polyzos SA; Kountouras J; Mantzoros CS; Polymerou V; Katsinelos P
    Diabetes Obes Metab; 2017 Dec; 19(12):1805-1809. PubMed ID: 28452101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nutrigenomics analysis reveals that copper deficiency and dietary sucrose up-regulate inflammation, fibrosis and lipogenic pathways in a mature rat model of nonalcoholic fatty liver disease.
    Tallino S; Duffy M; Ralle M; Cortés MP; Latorre M; Burkhead JL
    J Nutr Biochem; 2015 Oct; 26(10):996-1006. PubMed ID: 26033743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of aldose reductase ameliorates diet-induced nonalcoholic steatohepatitis in mice via modulating the phosphorylation of hepatic peroxisome proliferator-activated receptor α.
    Chen T; Shi D; Chen J; Yang Y; Qiu M; Wang W; Qiu L
    Mol Med Rep; 2015 Jan; 11(1):303-8. PubMed ID: 25333350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease.
    Ganesh S; Rustgi VK
    Clin Liver Dis; 2016 May; 20(2):351-64. PubMed ID: 27063274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.